The drug sorafenib — already approved in several countries for treatment of kidney and liver cancer — dramatically improves the health of rats with liver cirrhosis and advanced portal hypertension.
A new mouse model of melanoma has given researchers hope that they can better target malignant skin cancers in humans — with a promising combination of two drug therapies.